Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Take the Money and Run -- Ignore unavailable to you. Want to Upgrade?

To: Rainy_Day_Woman who wrote (13524)	8/6/2002 4:14:12 PM
From: Peach	Read Replies (1) \| Respond to of 17639

How much are you asking, Foxy?

To: Rainy_Day_Woman who wrote (13524)	8/6/2002 4:17:22 PM
From: Jorj X Mckie	Read Replies (1) \| Respond to of 17639

16:13 ET BABY Natus Medical misses by four cents (3.57 +0.02) Reports Q2 (Jun) loss of $0.12 per share, $0.04 worse than the Multex consensus of ($0.08); revenues fell 9.7% year/year to $6.5 mln vs the $7.2 mln consensus; company reported cash, cash equivalents and short-term investments of $49.6 million and working capital of $54.5 million at June 30, 2002. 16:12 ET TMPW falls 11% on COO departure; still waiting on earnings release 16:09 ET EXEL Exelixis beats by 2 cents, guides below consensus (5.48 +0.45) -- Update -- Reports Q2 pro forma loss of $0.39, $0.02 better than the Multex consensus; revs were $9.9 mln, vs consensus of $9.8 mln. Co expects Q3 rev to grow 7-12% sequentially (about $10.6-$11.1 mln, below consensus of $13.6 mln), and expects 2002 rev to grow 7-12% from the prior year (about $43.9-$45.9 mln, below consensus of $51.0 mln). 16:09 ET GDT Guidant receives FDA approval of defibrillation lead (33.47 +0.40) Company announces it has received FDA approval of its ENDOTAK RELIANCE active-fixation defibrillation lead; says product will be market released later this month.